BioPharma Dive July 30, 2024
The company will stop developing five experimental treatments, including two oral checkpoint inhibitors targeting PD-L1.
Dive Brief:
- Incyte is cutting down its pipeline of experimental cancer drugs, announcing Tuesday that it will no longer invest in five immunotherapies it’s been testing in early clinical trials.
- Among the discontinued programs are two so-called checkpoint inhibitors targeting a protein known as PD-L1. Unlike similar drugs already on the market that are injected or infused, these two treatments were developed to be taken orally.
- Incyte is also stopping work on two antibodies discovered via a partnership with the biotechnology company Agenus, and a bispecific antibody being developed in collaboration with Merus. Incyte previously cut a handful of early pipeline programs last May. ...
Today's Sponsors
Today's Sponsor